US FDA prepares to face generic drug labeling rule critics

The US Food and Drug Administration is to confront critics of its proposed rule in November 2013 to allow generic drug makers to independently revise their product labeling to add new safety updates before the regulators review or approve such changes – in the same way that brand-name manufacturers do already1-3.